NovoCure Limited: Profitability Remains Elusive

2025-05-21 18:43:20 ET

Summary

• NovoCure Limited beat Q1 expectations and highlighted some positive pipeline updates, but NVCR shares remain well below recent highs.
• Analysts remain bullish, with multiple Buy ratings and price targets in the $33–$38 range, despite some ongoing insider selling in 2024 and 2025.
• The company’s strong balance sheet, with $930 million in cash and low debt, supports its growth plans despite continued quarterly losses.
• An updated analysis around NovoCure Limited follows in the paragraphs below.

Today, I am putting NovoCure Limited ( NVCR ) in the spotlight. The stock has gotten a bit of bump after beating quarterly expectations late in April and outlining its expansion plans. However, the stock is still significantly below its recent highs in late 2024. More upside in the shares? An analysis follows below....

Read the full article on Seeking Alpha

For further details see: